#Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized #COVID-19 patients

Patients with coronavirus disease-19 (COVID-19) are at high risk for thrombotic arterial and venous occlusions. However, bleeding complications have also been observed in some patients. Understanding the balance between coagulation and fibrinolysis will help inform optimal approaches to thrombosis prophylaxis and potential utility of fibrinolytic-targeted therapies. 118 hospitalized COVID-19 patients and 30 healthy controls were included in the study. We measured plasma antigen levels of … Continue reading #Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized #COVID-19 patients

Rate This

Fecal #microbiota transplant overcomes resistance to anti–PD-1 therapy in #melanoma patients

Anti–programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to patients with advanced melanoma. The composition of the gut microbiota correlates with anti–PD-1 efficacy in preclinical models and cancer patients. To investigate whether resistance to anti–PD-1 can be overcome by changing the gut microbiota, this clinical trial evaluated the safety and efficacy of responder-derived fecal microbiota transplantation (FMT) together with anti–PD-1 in patients … Continue reading Fecal #microbiota transplant overcomes resistance to anti–PD-1 therapy in #melanoma patients

Rate This